LOS ANGELES, Sept. 26, 2023 /PRNewswire/ — Partillion Bioscience Corporation (“Partillion”), a life science tools company, today announced the closing of a $5 million seed financing round, expansion of its board of directors, and a multiyear agreement with Alloy Therapeutics, Inc. as a Preferred Partner providing antibody discovery services using Partillion’s Nanovial technology. Nanovials solve numerous industry challenges as the first microscale test tubes engineered for the isolation and analysis of individual cells that are compatible with standard laboratory equipment.
Read more here.
